Article Sidebar

PDF
Date Published: 09/10/2022
Abstract Views: 381
Views PDF: 250
DOI: https://doi.org/10.51298/vmj.v518i2.3481
Issue
Vol. 518 No. 2 (2022)
Section
Các bài báo
How to Cite
Nguyễn Khánh Linh, D. ., Thị Thái Hòa, N. ., & Thị Khánh Tâm, L. . (2022). EVALUATE THE RESULTS OF ABIRATERONE ACETATE + PREDNISOLON IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER. Vietnam Medical Journal, 518(2). https://doi.org/10.51298/vmj.v518i2.3481

EVALUATE THE RESULTS OF ABIRATERONE ACETATE + PREDNISOLON IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

Dương Nguyễn Khánh Linh1,, Nguyễn Thị Thái Hòa2, Lê Thị Khánh Tâm1
1 Friendship Hospital
2 Vietnam National Cancer Hospital

Main Article Content

Abstract

Objective: Evaluate the results of Abiraterone Acetate + Prednisolon in metastatic castration – resistant prostate cancer at Huu Nghi Hospital and K Hospital. Patients and methods: Retrospective descriptive study of 56 patients with metastatic castration – resistant prostate cancer at Huu Nghi Hospital and K Hospital from January 2015 to July 2022. Results: The mean age of patients was 74,18±7,93 years old. Common clinical symptoms at the diagnosis: bone pain (39,3%), dysuria (35,7%); urinary incontinence (30,4%); urinary retention (10,7%); hematuria (7,1%). Treatment results: the mojority of patients achieved PSA response (73,2%). Overall response rate (ORR) on images according to RECIST 1.1criteria reached 60,7%. Median progressione-free survival (PFS) was 15,8±3,8 months. Conclusion: The regimen gave good results for metastatic castration – resistant prostate cancer.

Article Details

Keywords

Abiraterone Acetate Prednisolon, Ung thư tuyến tiền liệt, giai đoạn di căn kháng cắt tinh hoàn

References

1. Ferlay J., Soerjomataram I., Dikshit R. và cộng sự. (2015). Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012: Globocan 2012. Int J Cancer, 136(5), E359–E386.
2. Ferlay J., Colombet M., Soerjomataram I. và cộng sự. (2019). Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer, 144(8), 1941–1953.
3. Tâm L.T.K. đánh giá kết quả điều trị nội tiết ung thư tuyến tiền liệt giai đoạn iv. 136.
4. Gandaglia G., Abdollah F., Schiffmann J. và cộng sự. (2014). Distribution of metastatic sites in patients with prostate cancer: A population-based analysis: Sites of Metastases in PCa Patients. Prostate, 74(2), 210–216.
5. Loblaw D.A., Mendelson D.S., Talcott J.A. và cộng sự. (2004). American Society of Clinical Oncology Recommendations for the Initial Hormonal Management of Androgen-Sensitive Metastatic, Recurrent, or Progressive Prostate Cancer. JCO, 22(14), 2927–2941.
6. Burgio S.L., Conteduca V., Rudnas B. và cộng sự. (2015). PSA Flare With Abiraterone in Patients With Metastatic Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer, 13(1), 39–43.
7. Miller K., Carles J., Gschwend J.E. và cộng sự. (2018). The Phase 3 COU-AA-302 Study of Abiraterone Acetate Plus Prednisone in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Stratified Analysis Based on Pain, Prostate-specific Antigen, and Gleason Score. European Urology, 74(1), 17–23.